NASDAQ : ALLO
Allogene Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 407.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 407.68M |
| Enterprise Value | 154.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 345.49M |
| Shares Outstanding | 345.49M |
| Shares Change (YoY) | +19.14% |
| Shares Change (QoQ) | +36.89% |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 73.23% |
| Float | 281.86M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 87.86 |
| Forward PS | 32,771.64 |
| PB Ratio | 0.93 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 33.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.72 |
| Quick Ratio | 10.55 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -138.71 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.39% |
| Return on Assets (ROA) | -22.08% |
| Return on Invested Capital (ROIC) | -23.81% |
| Return on Capital Employed (ROCE) | -34.79% |
| Weighted Average Cost of Capital (WACC) | 6.35% |
| Revenue Per Employee | $30,526 |
| Profits Per Employee | -$1.09M |
| Employee Count | 152 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -3.28% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 29.29 |
| Average Volume (20 Days) | 7,301,054 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 53.41M |
| Short Previous Month | 55.61M |
| Short % of Shares Out | 15.46% |
| Short % of Float | 18.95% |
| Short Ratio (days to cover) | 9.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.64M |
| Gross Profit | -117.88M |
| Operating Income | -180.32M |
| Pretax Income | -165.49M |
| Net Income | -165.49M |
| EBITDA | -168.65M |
| EBIT | -180.32M |
| Loss Per Share | -$0.65 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 332.60M |
| Total Debt | 79.01M |
| Net Cash | 253.60M |
| Net Cash Per Share | $0.73 |
| Equity (Book Value) | 436.18M |
| Book Value Per Share | 1.26 |
| Working Capital | 308.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -102.20M |
| Capital Expenditures | -402,000 |
| Depreciation & Amortization | 11.67M |
| Net Borrowing | n/a |
| Free Cash Flow | -102.60M |
| FCF Per Share | -$0.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,886.14% |
| Pretax Margin | -3,566.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.14% |
| Shareholder Yield | -19.14% |
| Earnings Yield | -55.11% |
| FCF Yield | -25.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.00 |
| Price Target Difference | 662.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.46 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |